Seoul, South Korea (PRWEB) June 28, 2016
BioCore Korea and Accium BioSciences, (Seattle, U.S.), international providers of pharmaceutical microtracer solutions, today entered an agreement to extend joint microtracer solutions to the global pharmaceutical industry.
“The collaboration between Accium and BioCore working makes great business sense”, states Dr. Dueker, former founder of Vitalea Science and now Managing Director at BioCore. “Both companies have specific business needs that are addressed in the partnership and we expect to expand the business collaboration as we gain experience working together”.
Microtracer clinical studies are isotope based analyses that enable characterization of the human metabolism and disposition of a developing drug often at the earliest stages of clinical development. These studies are widely viewed as one way to reduce late stage failures that can cost a pharmaceutical company hundreds of millions of dollars in time, resources, and lost opportunity.
"We are excited to embark on joining of specific services”, states Accium’s President and CEO, Glenn Kawasaki. “In doing so we will bring much needed efficiency the pharmaceutical AMS markets, and simplify the experience for our pharmaceutical customers”.
The two companies in fact already share a unique and common heritage - both companies can trace their core skillsets back to the pioneering days of biomedical Accelerator Mass Spectrometry research at the University of California and Lawrence Livermore National Laboratory. Accelerator Mass Spectrometry is an atomic counter of carbon isotopes was originally developed for archaeology as well as nuclear surveillance. It is associated with microdosing and microtracing in clinical research, though its full impact has yet to be realized.
The integration of the services of BioCore, Korea’s largest bioanalytical CRO and Accium, the first commercial provider of AMS services in the United States, brings scale and stability to the microtracer CRO business. BioCore will provide traditional mass spectrometry bioanalysis, metabolite identification, AMS sample pretreatment and clinical site management skills. Accium in turn provides access to its multiple AMS instruments and experienced pharmaceutical study directors.
The integration creates a single contact point for pharmaceutical companies that require both traditional and microtracer services during early clinical development. It also bridges the Asia-Pacific region, the fastest growing region for clinical microtracer studies. Korea in particular is investing heavily in these early clinical capabilities.
To learn more about AMS services provided by BioCore or Accium and this cooperative agreement, please contact Stephen Dueker (sdueker(at)bio-core(dot)com) or Accium BioSciences (info(at)acciumbio(dot)com) at (206) 281-3915 ext. 301.